Clinical Trial Update: Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Rituximab-induced B-cell depletion and its effects on T cells in systemic lupus erythematosus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Lupus Erythematosus, Systemic | Phase 2 | Status: WITHDRAWN